SALSA MLPA P077 BRCA2 Confirmation probemixCE

application: Breast cancer, hereditary
region: BRCA2
[login for my products]
version: B1
sold since: 2017-10-02

item no. description price
P077-025R SALSA MLPA P077 BRCA2 Confirmation probemix – 25 rxn € 237
P077-050R SALSA MLPA P077 BRCA2 Confirmation probemix – 50 rxn € 474
P077-100R SALSA MLPA P077 BRCA2 Confirmation probemix – 100 rxn € 948
EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 294
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 294
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1355
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1355

Please note that both a probemix and reagent kit are needed to perform MLPA.

Intended use: The SALSA MLPA probemix P077 BRCA2 Confirmation is an in vitro diagnostic (IVD)1 or a research use only (RUO) assay for the confirmation of deletions or duplications in the human BRCA2 gene as initially observed using the SALSA MLPA P090 BRCA2 probemix or SALSA MLPA P045 BRCA2/CHEK2 probemix. This P077 BRCA2 Confirmation probemix cannot be used to verify CHEK2 mutations found with P045. However, the P190 CHEK2 probemix is available for deletion or duplication analysis of other CHEK2 exons. This assay is for use with human DNA extracted from peripheral blood and not with DNA extracted from formalin-fixed paraffin embedded or fresh tumour materials. The probemix is not intended to be used as a standalone assay for clinical decisions. The results of this test should be interpreted by a clinical molecular geneticist or equivalent.

1Please note that this probemix is for In Vitro Diagnostic use (IVD) in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Clinical background: Breast and ovarian carcinomas are among the most common malignancies in developed countries. The majority of cases are considered sporadic, but in a substantial portion, a clear history of cases within a family is present. The BRCA1 and BRCA2 proteins are associated with the activation of double-strand break repair and homologous recombination and are important in maintaining genomic stability. Germline mutations in the BRCA1 and BRCA2 genes are linked to a high risk of young-onset hereditary breast and ovarian cancer. Features characteristic of hereditary, versus sporadic, breast cancer are: younger age at diagnosis, frequent bilateral disease, and more frequent occurrence of disease among male relatives. Mutations in the BRCA1 and BRCA2 genes account for about 20 to 25% of hereditary breast cancers (Easton 1999) and about 5 to 10% of all breast cancers (Campeau et al. 2008). In addition, mutations in the BRCA1 and BRCA2 genes cause around 15% of ovarian cancers overall (Pal et al. 2005). More information is available at

Deletions or duplications are more frequent for BRCA1 than for BRCA2. The prevalence of deletions or duplications is dependent on the studied population and ranges from 0% to 11% of all BRCA2 mutations (Agata et al. 2005, Woodward et al. 2005, Casilli et al. 2006, Stadler et al. 2010).

P077-B1 probemix content: This SALSA MLPA probemix P077-B1 BRCA2 Confirmation contains 50 MLPA probes with amplification products between 124 and 502 nt (Table 1) including 38 probes for the BRCA2 gene region (Table 2) and 12 reference probes that detect sequences outside this region. The identity of the genes detected by the reference probes is available online ( At least one MLPA probe is present for each exon in the BRCA2 transcript. In addition, one probe is included for introns 3, 7, 12 and 13; two probes are included for exons 8, 16, 18 and 27; three probes are included for the large exon 11; and one probe is included for the region upstream of exon 1.

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity Fragments (Q-fragments), three DNA Denaturation Fragments (D-fragments), and one chromosome X and one chromosome Y-specific fragment (Table 1). The Q-fragments are only visible when less than 100 ng sample DNA is used. Low signal of the 88 and 96 nt fragments indicates incomplete DNA denaturation. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol.

Positive control DNA samples: In case no positive DNA sample is available in your laboratory, an artificial duplication DNA sample for this probemix (catalogue number SD024) can be ordered from MRC-Holland. This SD024 Artificial Duplication DNA will show a duplication of several probes when using the following probemixes: P002 and P087 BRCA1; P045, P090 and P077 BRCA2. The SD024 Artificial Duplication DNA is a mixture of human female genomic DNA and a titrated amount of plasmid containing selected probe target sequences. For further details, please consult the SD024 Artificial Duplication DNA product description, available online: This SD024 is for research use only (RUO).

sample DNA
Sample DNA developed for this product:

related products
SALSA MLPA P002 BRCA1 probemix
Hereditary breast cancer, primary screening BRCA1.
SALSA MLPA P041 ATM-1 probemix
Mutations in ATM have been linked to a higher risk on breast cancer.
SALSA MLPA P042 ATM-2 probemix
Mutations in ATM have been linked to a higher risk on breast cancer.
SALSA MLPA P045 BRCA2/CHEK2 probemix
Hereditary breast cancer, primary screening BRCA2.
Mutations in PALB2 have been linked to a higher risk on breast cancer.
SALSA MLPA P087 BRCA1 Confirmation probemix
Hereditary breast cancer, confirmation BRCA1.
SALSA MLPA P090 BRCA2 probemix
Identical to P045 BRCA2/CHEK2, but does not contain probes for CHEK2.
SALSA MLPA P190 CHEK2 probemix
Breast cancer susceptibility, genes included: CHEK2, ATM, BRCA1&2, PTEN, TP53.
SALSA MLPA P239 BRCA1 region probemix
Characterization of BRCA1 deletions/duplications.
SALSA MLPA P240 BRIP1/CHEK1 probemix
Mutations in BRIP1 have been linked to a higher risk on breast cancer.
SALSA MLPA P260 PALB2-RAD50-RAD51C-RAD51D probemix
Mutations in these genes have been linked to a higher risk on breast cancer.

product history
version B1: As compared to the previous version, 14 target probes are replaced, 6 reference probes are replaced and 2 extra reference probes are added.
version A3: The length of the BRCA2 exon 11 probe has been adjusted, no change in hybridising sequence detected
version A2: One reference probe and the 88 and 96 nt control fragments have been replaced (QDX2). One extra reference probe has been included and three probes have a small change in length.
version A1: changes not specified

new products
Adrenocortical tumours and other solid tumours
improved products
Li-Fraumeni syndrome (LFS) and tumour analysis
P175-Tumour Gain
Tumour Gain
Hereditary predisposition to Cancer
Dihydropyrimidine dehydrogenase (DPYD) deficiency
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland